Impedimed Limited Stock Performance
| IPDQF Stock | USD 0.02 0 13.33% |
ImpediMed holds a performance score of 7 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -2.67, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ImpediMed are expected to decrease by larger amounts. On the other hand, during market turmoil, ImpediMed is expected to outperform it. Use ImpediMed Limited skewness, as well as the relationship between the day median price and relative strength index , to analyze future returns on ImpediMed Limited.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ImpediMed Limited are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent basic indicators, ImpediMed reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 19.7 M | |
| Total Cashflows From Investing Activities | -5.2 M | |
| Free Cash Flow | -20.9 M |
ImpediMed |
ImpediMed Relative Risk vs. Return Landscape
If you would invest 1.18 in ImpediMed Limited on November 6, 2025 and sell it today you would earn a total of 0.52 from holding ImpediMed Limited or generate 44.07% return on investment over 90 days. ImpediMed Limited is currently producing 1.2505% returns and takes up 12.7101% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than ImpediMed, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
ImpediMed Target Price Odds to finish over Current Price
The tendency of ImpediMed Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 46.48 |
Based on a normal probability distribution, the odds of ImpediMed to move above the current price in 90 days from now is about 46.48 (This ImpediMed Limited probability density function shows the probability of ImpediMed Pink Sheet to fall within a particular range of prices over 90 days) .
ImpediMed Price Density |
| Price |
Predictive Modules for ImpediMed
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ImpediMed Limited. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ImpediMed Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ImpediMed is not an exception. The market had few large corrections towards the ImpediMed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ImpediMed Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ImpediMed within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.24 | |
β | Beta against Dow Jones | -2.67 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.09 |
ImpediMed Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImpediMed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImpediMed Limited can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImpediMed Limited is way too risky over 90 days horizon | |
| ImpediMed Limited has some characteristics of a very speculative penny stock | |
| ImpediMed Limited appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 10.49 M. Net Loss for the year was (19.87 M) with profit before overhead, payroll, taxes, and interest of 9.16 M. | |
| ImpediMed Limited has accumulated about 40.73 M in cash with (15.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company shares are held by company insiders |
ImpediMed Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ImpediMed Pink Sheet often depends not only on the future outlook of the current and potential ImpediMed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ImpediMed's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.8 B | |
| Shares Float | 1.6 B |
ImpediMed Fundamentals Growth
ImpediMed Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of ImpediMed, and ImpediMed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImpediMed Pink Sheet performance.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.88) % | |||
| Operating Margin | (2.00) % | |||
| Current Valuation | 81.27 M | |||
| Shares Outstanding | 1.79 B | |||
| Price To Earning | (8.46) X | |||
| Price To Book | 2.74 X | |||
| Price To Sales | 9.22 X | |||
| Revenue | 10.49 M | |||
| EBITDA | (18.77 M) | |||
| Cash And Equivalents | 40.73 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 170 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (15.66 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 58.7 M | |||
| Retained Earnings | (150 M) | |||
| Current Asset | 88 M | |||
| Current Liabilities | 5 M | |||
About ImpediMed Performance
By analyzing ImpediMed's fundamental ratios, stakeholders can gain valuable insights into ImpediMed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImpediMed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImpediMed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy devices and software services in Australia, North America, and internationally. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia. Impedined operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 73 people.Things to note about ImpediMed Limited performance evaluation
Checking the ongoing alerts about ImpediMed for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for ImpediMed Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImpediMed Limited is way too risky over 90 days horizon | |
| ImpediMed Limited has some characteristics of a very speculative penny stock | |
| ImpediMed Limited appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 10.49 M. Net Loss for the year was (19.87 M) with profit before overhead, payroll, taxes, and interest of 9.16 M. | |
| ImpediMed Limited has accumulated about 40.73 M in cash with (15.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company shares are held by company insiders |
- Analyzing ImpediMed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImpediMed's stock is overvalued or undervalued compared to its peers.
- Examining ImpediMed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImpediMed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImpediMed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImpediMed's pink sheet. These opinions can provide insight into ImpediMed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImpediMed Pink Sheet analysis
When running ImpediMed's price analysis, check to measure ImpediMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImpediMed is operating at the current time. Most of ImpediMed's value examination focuses on studying past and present price action to predict the probability of ImpediMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImpediMed's price. Additionally, you may evaluate how the addition of ImpediMed to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |